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Successful cancer therapy requires the elimination
or incapacitation of all tumor cells capable of regen-
erating a tumor. Therapeutic advances therefore
necessitate the characterization of the cells that are
able to propagate a tumor in vivo. We show an
important link between tumor genotype and isolation
of tumor-propagating cells (TPCs). Three mouse
models of the most common form of human lung
cancer each had TPCs with a unique cell-surface
phenotype. The cell-surface marker Sca1 did not
enrich for TPCs in tumors initiated with oncogenic
Kras, and only Sca1-negative cells propagated
EGFR mutant tumors. In contrast, Sca1-positive
cells were enriched for tumor-propagating activity
in Kras tumors with p53 deficiency. Primary tumors
that differ in genotype at just one locus can therefore
have tumor-propagating cell populations with
distinct markers. Our studies show that the genotype
of tumor samples must be considered in studies
to identify, characterize, and target tumor-propa-
gating cells.
INTRODUCTION
Identification of functionally important tumor cell populations
with the ability to propagate the tumor phenotype in vivo
(tumor-propagating cells [TPCs]) promises to elucidate mecha-
nisms of tumorigenesis and potential new therapeutic targets.
Molecularly defined tumor cell populations with such capacity
(often referred to as cancer stem cells or tumor-initiating cells)
have been identified in a variety of malignancies, yet in some
cancers, nearly every cell has tumor-propagating ability (re-
viewed in Shackleton et al., 2009; Visvader and Lindeman,
2008). Although tumor genotype is known to influence response
to targeted therapies, the identity of tumor-propagating cells in
cancers with different genotypes has not been compared.We used genetically defined murine models to identify lung
tumor-propagating cells. In two murine models of the most
common form of lung cancer, adenocarcinoma, tumors are initi-
ated with conditional activation of oncogenic K-rasG12D from the
Lox-Stop-Lox-KrasG12D allele alone (hereafter, Kras) (Jackson
et al., 2001) or with conditional p53 deficiency in p53flox/flox
mice (hereafter, Kras;p53-flox) (Jackson et al., 2005). Both
models yield non-small-cell lung cancers, specifically adenocar-
cinomas, and recapitulate key aspects of human lung cancers
(Jackson et al., 2005; Jackson et al., 2001). Mice bearing
a mutant human epidermal growth factor receptor transgene,
EGFRT790M-L858R (hereafter, EGFR), develop adenocarcinomas
representative of lung cancer found in nonsmokers (Li et al.,
2007). Importantly, EGFR mutant tumors are histologically
similar to the tumors in the Kras and Kras;p53-flox mice.
We hypothesized that isolating cells positive for the cell-
surface marker of stem/progenitor cells in the corresponding
normal tissue would prove useful in identification of lung TPCs.
Although CD133-positive human lung cancer cells have propa-
gating activity in sphere cultures and subcutaneous injections
(Chen et al., 2008; Eramo et al., 2008; Jiang et al., 2009), lung
TPCs with demonstrable self-renewal and differentiation in the
lung microenvironment have not been reported. We and others
have used Sca1 (Ly6a) cell-surface expression to identify stem
cells in the normal murine lung (Kim et al., 2005; McQualter
et al., 2009; McQualter et al., 2010; Teisanu et al., 2009), making
it an interesting marker to test in murine lung cancer.
Orthotopic transplantations of lung adenocarcinoma cells
yielded secondary tumors that recapitulated the features of the
primary lung tumors. Sca1-positive cells from Kras;p53-flox
tumors were highly enriched for tumor-propagating activity.
Sca1 status did not enrich for TPCs in Kras tumors and only
Sca1-negative cells propagated EGFR tumors. Thus, primary
tumor genotype is an important determinant of the cell-surface
phenotype of lung tumor-propagating cell populations.
RESULTS
Orthotopic Lung Tumor Transplantation Assay
We first established an orthotopic transplantation assay for
propagating lung tumor cells in vivo. Primary adenocarcinomasCell Stem Cell 7, 127–133, July 2, 2010 ª2010 Elsevier Inc. 127
Figure 1. Orthotopic Transplantation of Kras and Kras;p53-flox
Tumor Cells Recapitulates the Primary Tumor Phenotype
(A) Cartoon of the transplantation scheme used to assay lung tumor-propa-
gating cells (TPCs) through serial transplantation.
(B) H&E staining of primary (left) and secondary (right) Kras lung adenocarci-
nomas showing similar pathological grade, nuclear features, and general
tumor architecture.
(C) H&E staining of primary (left) and secondary (right) Kras;p53-flox lung
tumors showing similar histopathological characteristics of advanced adeno-
carcinoma, including pleomorphic nuclei and rare giant cells. All images are
shown at 2003 magnification. The scale bar represents 100 mM.
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single-cell suspensions and transplanted intratracheally (IT)
into recipient mice (Figure 1A). Secondary tumors formed in
recipient mice 4 to 8 months (average 5.5 months) after IT trans-
plant of 103 to 106 cells. The secondary adenocarcinomas reca-
pitulated the histopathology of the primary tumors (Figure 1B),
validating this assay for lung cancer cell function. Secondary
Kras;p53-flox tumors also recapitulated the adenocarcinoma
histopathology of the corresponding primary tumors (Figure 1C).
Limiting dilution analysis performed by injecting various numbers
of tumor cells indicated that the frequency of TPCs was not
significantly different between the two models (1 out of 10,000
Kras;p53-flox tumor cells gave rise to a tumor versus 1 out of
12,000 Kras tumor cells, p = 0.78, data not shown). Thus, the
ability to isolate and functionally test TPCs in these two models
was similar using our transplantation assay.
Prospective Isolation of Tumor-Propagating Cells
We next sought to determine whether lung tumor-propagating
cells could be identified prospectively from Kras;p53-flox
tumors by using expression of Sca1, a marker of normal lung
stem/progenitor cells. The fraction of CD45-negative CD31-nega-
tive Sca1-positive cells (hereafter, Sca1+ cells) within Kras;p53-
flox tumors ranged from 0.56% to 1.74% (average 1.11%)
of tumor cells (Figure 2A and data not shown). The majority of
the remaining nonhematopoietic and nonendothelial cells con-
sisted of Sca1-negative, highly autofluorescent cells (hereafter,
Sca1– cells).
To compare the tumor-propagating capacity of each popula-
tion, we performed limiting dilution transplantations with
Kras;p53-flox Sca1+ or Sca1 cells (Figure 2A, Table 1, and
Table S1, available online). We observed a highly significant 5-
fold enrichment for tumor-propagating potential in the Sca1+
population compared to the Sca1 population (p = 0.0006);
1 in 1489 Sca1+ cells had tumor-propagating activity, compared
to 1 in 7567 Sca1 cells. Secondary tumors from Sca1+ cells
recapitulated the primary lesions (compare Figure 2B with
Figure 1C), whereas the few secondary tumors that formed
from Sca1– cell transplants exhibited a smaller, more diffuse
phenotype (Figure 2B and Figure S1A, p = 0.046). Most cells in
murine lung adenocarcinomas express the alveolar type II
(AT2) cell differentiation marker surfactant protein C (SP-C) and
do not stain for the bronchiolar Clara cell differentiation marker
Clara cell secretory protein (CCSP) with the exception of rare
SP-C+ CCSP+ cells (Jackson et al., 2001; Kim et al., 2005).
Secondary tumors arising from Sca1+ cells shared the same
staining pattern for these lung cell markers (Figure 2C), indicating
a similar differentiation pattern of the primary tumors and the
Sca1+ cell derived secondary tumors. Further demonstrating
the differentiation capacity of Sca1+ tumor cells, the overall
abundance of Sca1+ and Sca1 cells was re-established in the
secondary tumors derived from injection of Sca1+ cells
(Figure S1B). In contrast, only Sca1 cells were present in
a secondary tumor derived from Sca1 cells (Figure S1B).
Finally, expression analysis for several other markers suggested
that the primary Sca1 cells were more differentiated than Sca1+
cells (Figure S1C).
We next used serial transplantation to determine whether the
Sca1+ Kras;p53-flox tumor cells had the stem cell property of128 Cell Stem Cell 7, 127–133, July 2, 2010 ª2010 Elsevier Inc.self-renewal. Secondary tumor cells derived from Sca1+
Kras;p53-flox tumor cell transplants gave rise to tertiary tumors
that were similar to the corresponding primary and secondary
tumors (Figure 2D), and the Sca1+ fraction of secondary tumors
more frequently yielded tumors after transplantation than the
Sca1 fraction (Figure S1D). Importantly, secondary tumor cells
derived from Sca1 Kras;p53-flox tumor cell transplants were
unable to yield tertiary tumors (Figure 2D and Figure S1D). There-
fore, the Sca1+ cells from Kras;p53-flox tumors were capable of
differentiation and self-renewal in serial transplantations,
whereas Sca1 cells appeared more differentiated and did not
self-renew.
We confirmed that our ability to detect an enrichment of TPCs
in the Sca1+ population from Kras;p53-flox tumors did not result
from a lack of tumor cells in the Sca1 fraction by using several
different assays. First, we performed one-lox recombination
specific PCR, in which a PCR product is obtained only from
the recombined allele after effective Cre activity, to assess the
status of the floxed Kras and p53 loci in the sorted cell popula-
tions and confirm the presence of tumor cells. Although we did
observe tumor-to-tumor variability, the amount of recombination
Figure 2. Sca1+ Cells from Kras;p53-flox Tumors Are Lung Tumor-
Propagating Cells
(A) Representative FACS analysis of Kras;p53-flox tumor cells used for trans-
plantation (top). Limiting dilution transplantation of the sorted cells indicated
that the Sca1+ population was significantly enriched for TPCs (table).
(B) Sca1 cell transplants yielded smaller, more diffuse lesions (left), whereas
Sca1+ cell transplants yielded secondary tumors that recapitulated the
histopathology of primary Kras;p53-flox tumors (right, compare to Figure 1C).
(C) Immunofluorescence (IF) staining with antisera raised against SP-C (red),
CCSP (green), and counterstain DAPI (blue) showed that primary Kras;p53-
flox lung adenocarcinomas (left) are mainly composed of SP-C+ cells, a pattern
recapitulated in secondary tumors from Sca1+ cell transplants (right).
(D) Serial transplantation of secondary tumor cell populations revealed a lack of
tumor formation from Sca1 cells (left), in contrast to tertiary tumor develop-
ment from Sca1+ cells (right). All images are shown at 2003 magnification.
The scale bar represents 100 mM. See also Figure S1 and Table S1 for addi-
tional data.
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cells within each tumor sample (Figure S1E). Second, we
compared the transplantation efficiency of the Kras;p53-flox
tumor cell populations by using a GFP allele to mark and identify
transplanted tumor cells. The percentage of GFP+ cells detected
after transplantation of Sca1+ cells was not significantly different
than after transplantation of Sca1- cells (Figure S1F, 0.84% and
0.62%, respectively, p = 0.501). Notably, these transplantation
efficiencies were much greater than that of normal lung cells
(0.015% –0.033%; D. Raiser and C.F.K., unpublished data), sug-
gesting that both populations were capable of initial expansion
in vivo as expected for tumor cells. Finally, the cell-cycle status
of Sca1+ cells did not significantly differ from that of Sca1 cells
(Figure S1G).
Comparison of Lung Tumor-Propagating Cell Phenotype
between Mouse Models
Having identified Sca1+ cells as the TPCs in the Kras;p53-flox
model, we next wished to determine whether the same marker
could identify TPCs in Kras lung tumors. The frequency of
Sca1+ cells in Kras tumors was similar to that in Kras;p53-flox
tumors (range: 0.4%–2.9%, average: 0.95%, p = 0.69) (Figures
3A and 2A, data not shown). Sca1+ cells from Kras and
Kras;p53-flox tumors expressed CCSP and SP-C, whereas
Sca1 cells from both tumor genotypes expressed very high
levels of SP-C and virtually no CCSP (Figure S2A), confirming
that Sca1 staining was valid for sorting similar cells from Kras
and Kras;p53-flox tumors.
Surprisingly and in contrast to the Kras;p53-flox tumors, the
Sca1+ and Sca1 cells from Kras tumors were equally capable
of forming secondary tumors (Figure 3A, Table 1, and
Table S2). The TPC frequencies were 1 out of 13,990 Sca1+ cells
and 1 out of 16,097 Sca1 cells (p = 0.7311). The secondary
tumors derived from Sca1+ cells and Sca1 cells were similar
to the primary tumors (compare Figure 3B to Figure 1B) and
were indistinguishable by histology, differentiation status (deter-
mined by FACS analysis for Sca1 and the pattern of staining for
CCSP and SP-C), size, and proliferative index (Figure 3C and
Figure S2B, data not shown). Finally, Sca1+ and Sca1 cells iso-
lated from Kras secondary tumors were capable of yielding
tertiary and quaternary tumors in serial transplant assays
(Figure 3D and Figure S2C, data not shown), suggesting that
both populations were capable of self-renewal. In summary,
Sca1 provided no enrichment for tumor-propagating capacity
in Kras lung tumors, whereas Sca1+ cells were a uniquely self-re-
newing tumor-propagating cell population in Kras mutant tumor
cells lacking p53.
Importantly, we confirmed the difference in tumor cell geno-
type in fractionated cells from Kras and Kras;p53-flox tumors.
First, recombination analysis confirmed that Kras tumors re-
tained p53 (Figure S2D). Second, we verified that p53 expression
was retained in Sca1+ and Sca1 Kras tumor cells and was not
detectable in most of the fractionated Kras;p53-flox tumor cells
(Figure S2E).
Our results with Kras and Kras;p53-flox tumors suggested that
lung cancers of different genotypes contain TPCs with distinct
phenotypes, so we next tested this hypothesis in a third model
of lung adenocarcinoma: EGFR mutant tumors. EGFR tumors
had a Sca1, CD31, and CD45 staining pattern nearly identicalCell Stem Cell 7, 127–133, July 2, 2010 ª2010 Elsevier Inc. 129
Table 1. Transplantation Results of Tumor Cell Populations
Number of Cells Transplanted
<100 100–1K 1K–5K 5K–10K 10K–100K >100K
Tumor Genotype Cell Type Number of Mice with Tumors/Number Transplanted (%) Frequency of TPCsa p Value
Kras;p53-flox Sca1+ cells 3/5 (60%) 2/3 (67%) 10/14 (71%) 2/2 (100%) ND ND 1/1489 0.0006b
Sca1 cells ND 2/9 (22%) 6/17 (35%) 2/4 (50%) ND ND 1/7567
Kras Sca1+ cells ND 1/4 (25%) 3/10 (30%) 5/11 (45%) 5/8 (63%) ND 1/13990 0.7311c
Sca1 cells ND 1/3 (33%) 4/8 (50%) 14/18 (78%) 4/6 (67%) 7/8 (88%) 1/16037
Varied numbers of tumor cells as indicated were transplanted in sterile PBS into Foxn1nu (nude) recipients. The number of recipient mice with at least
one secondary tumor was determined by histological analysis. Results shown are the combination of 14 and 9 different transplantation experiments
with Kras and Kras;p53-flox tumor cells, respectively. See also Tables S1 and S2 for more details.
a TPCs, Tumor-propagating cells. The frequency of cells with tumor-propagating capacity in the population was determined by limiting dilution analysis
with L-calc software using the transplanted cell numbers shown in Tables S1 and S2.
b Kras;p53-flox Sca1+ cells versus Kras;p53-flox Sca1 cells.
c Kras Sca1+ cells versus Kras Sca1 cells. ND, not determined.
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Sca1+ (Figure S2F). Strikingly, only the Sca1 cells were capable
of propagating EGFR tumors (Figure S2G) when either 5,000
cells (0/2 for Sca1+ and 3/3 for Sca1) or 25,000 cells (0/2 for
Sca1+ and 4/4 for Sca1) were transplanted. Importantly, both
populations expressed the mutant EGFR transgene at equal
levels (Figure S2H). Thus, EGFR tumors contained TPCs distinct
from those in Kras-driven lung tumors.
DISCUSSION
Our work indicates that lung adenocarcinomas of differing geno-
types have tumor-propagating cells with distinct markers. In
Kras;p53-flox tumors, positive selection for the surface marker
Sca1 enriches for cancer cells capable of self-renewal and differ-
entiation. In contrast, Sca1 does not select for TPCs in Kras or
EGFR mutant lung tumors. The study of functionally important
cells in lung cancers therefore requires a different strategy for
isolation of tumor-propagating cells from each model. On
a broader scale, the genotype of tumor samples must be taken
into account in studies to identify, characterize, and target
tumor-propagating cells in lung cancers and other malignancies.
It is clear that histologically distinct tumors contain tumor-
propagating populations with different markers. For example,
cells with a granulocyte-macrophage progenitor phenotype are
the candidate tumor-propagating cells in chronic myelogenous
leukemia (Jamieson et al., 2004), whereas in acute myelogenous
leukemia, the tumor-propagating cells more closely resemble
hematopoietic stem cells or multipotent progenitors (Bonnet
and Dick, 1997). Murine mammary tumorigenesis driven by
Wnt leads to the development of heterogeneous adenocarci-
nomas with various features of differentiation, whereas the
Her2/neu oncoprotein promotes the development of more
homogenous luminal epithelial tumors in mice, and these two
distinct subtypes of breast cancer appear to have different
tumor-propagating cell populations (Cho et al., 2008; Liu et al.,
2007; Vaillant et al., 2008). Finally, human and murine brain
cancers also appear to have distinct TPC markers (Read et al.,
2009; Ward et al., 2009). Importantly, prior to the present study
no direct comparisons had been made between tumor-propa-
gating cell populations within tumors of the same tissue origin130 Cell Stem Cell 7, 127–133, July 2, 2010 ª2010 Elsevier Inc.and same histopathological subtype with human or murine
samples.
Our results indicate that the same marker or set of markers
may not identify tumor-propagating cells in all patient samples
of a specific tumor type. CD44-positive, CD24-negative/low-
tumor cells propagated tumors from invasive lobular carcinomas
and adenocarcinomas from breast cancer patients (Al-Hajj et al.,
2003). In another study, however, a marker signature including
positive CD24 status identified breast cancer-propagating cells
in patient samples (Pece et al., 2010). The utility of seemingly
different marker sets in these studies may be due to differences
in the genotype of breast tumor specimens as we observed for
lung tumors. It has been possible to identify tumor-propagating
cells with the same marker across multiple patient samples
without regard to tumor genotype in some tissues. For example,
CD133+ cells were the tumor-propagating population in medul-
loblastomas and glioblastomas (Singh et al., 2004). Therefore,
it is possible that our results indicate a role for genotype in
TPC phenotype that is specific to lung cancer or that our results
are attributable to important distinctions between genetically
defined mouse models and tumors found in patients. However,
it is clear that currently known TPC populations are not homog-
enous. We reason that more precise purification of TPCs will
need to take into account the genotype of tumor samples. Sepa-
rating specimens according to genotype may reveal important
patterns in the tumor-propagating activity of isolated cell popu-
lations that cannot be observed by combining results from all
tumors. A retrospective analysis of the predominant genetic
changes found in the patient samples from which TPCs have
been identified may stratify the utility of marker combinations
and be a first step to addressing this possibility.
It will be particularly important to consider genotype in the
definition of tumor-propagating cells in human lung cancer,
given the diversity of genetic mutations and tumor subtypes
found in patient lung cancers. Our study has focused on three
murine models of adenocarcinoma, representing the three
most commonly mutated genes in human lung cancer: among
smokers, TP53 and KRAS mutations are the most common
(71% and 21% of patients, respectively), whereas EGFR muta-
tions are more commonly found in never-smokers (58% of
patients) (reviewed in Sun et al., 2007). At least 26 different genes
Figure 3. The Sca1+ and Sca1 Populations from Kras Lung Tumors
Are Equally Capable of Propagating Tumors
(A) Representative FACS analysis of Kras tumors showing a pattern of Sca1
staining similar to Kras;p53-flox tumors (top, compare to Figure 2A). Limiting
dilution transplantation indicated that Sca1+ and Sca1 Kras tumor cells are
identical in tumor-propagating potential (table).
(B) Secondary tumors from Sca1 (left) and Sca1+ (right) Kras tumor cell trans-
plants displayed similar pathological features.
(C) IF analysis of secondary tumors (as in Figure 2) revealed similar SP-C and
CCSP marker status in secondary tumors from Sca1 cells (left) and Sca1+
cells (right).
(D) Both Sca1- Kras tumor cells (left) and Sca1+ tumor cells (right) were
capable of serial transplantation to form tertiary tumors. All images are shown
at 2003 magnification. The scale bar represents 100 mM. See also Figure S2
and Table S2 for additional data.
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and additional mutations probably exist (Ding et al., 2008). These
separate genotypes of adenocarcinoma are usually indistin-
guishable at the histological level and until recently were largely
treated with the same chemotherapeutics, albeit unsuccessfully.
Identification of tumor-propagating cell populations to target in
these patient subsets, as in the mouse models shown here,
may offer new therapeutic approaches. Although each human
lung tumor sample is expected to be genetically distinct, there
are predominant mutations in human lung adenocarcinomas
that are known to predict response to targeted therapies and
that may be the most informative for studies of TPCs. We
suggest that those seeking to identify human lung TPCs geno-
type their tumor samples for these loci (KRAS, BRAF, EGFR,
HER2, ALK fusion, and PIK3CA) (Herbst et al., 2008) and deter-
mine whether their tumor propagation results correlate with
mutation status. Finally, several other subtypes of lung cancer,
such as squamous cell carcinoma, small-cell lung cancer, and
large-cell carcinoma, have known, common genetic mutations
distinct from those found in adenocarcinomas and these
subtypes remain to be examined for tumor-propagating cells in
murine or human samples.
Our findings have important implications for the development
of novel directed therapeutics. Successful cancer therapy
necessitates the eradication or permanent incapacitation of all
tumor cells with the ability to generate a tumor. It is well estab-
lished that primary tumor genotype can influence therapeutic
response in lung cancer. Patients with lung adenocarcinomas
bearing EGFR mutations exhibit a beneficial response to treat-
ment with EGFR inhibitors but unfortunately develop drug resis-
tance, whereas few patients lacking EGFR mutations have
response to such treatment (reviewed in Sun et al., 2007).
Furthermore, patients withKRASmutant lung cancers are partic-
ularly resistant to virtually all therapeutic options (Riely et al.,
2009). Our data now extend the idea that lung tumor genotype
influences therapeutic response. Knowledge of each patient’s
tumor genotype and TPC phenotype may be needed in combi-
nation to optimize therapeutic selection for any tumor type.
Future therapeutics designed to target tumor-propagating cells
found in some patients’ tumors might not be equally effective
against other patients’ tumors if their genotype is distinct.
Our data establish concepts that will be invaluable for further
work to define the mechanisms that regulate tumor propagation
in lung cancer and diverse malignancies. This is the first report of
lung cancer cells with self-renewal and differentiation capacity in
an orthotopic transplantation assay. It will be important to test
additional markers for TPCs in the different lung tumor geno-
types (especially including markers that can be used in human
lung cancer samples), to identify markers for further enrichment
of Kras;p53-flox lung TPCs, to compare TPC function in lung
tumors over time with tumor progression, and to determine
if and how discrete lung cancer cell populations differentially
respond to therapeutics. It will also be interesting to determine
the degree to which the cell of origin of genetically distinct lung
tumors overlap and how these cells relate in phenotype to
TPCs. Further understanding of the influence of genotype on
tumor propagation could lend insight toward developing better
therapeutic approaches for cancer patients. Whether the
tumor-propagating cells within a given tumor type are a rareCell Stem Cell 7, 127–133, July 2, 2010 ª2010 Elsevier Inc. 131
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nature yet rare tumor cells, or virtually all cells within a tumor, it
will be crucial to further understand the genetic and epigenetic
contributions that drive these important tumor cells.EXPERIMENTAL PROCEDURES
Mice and Tissues
Lox-Stop-Lox-KrasG12D mice and Lox-Stop-Lox-KrasG12D;p53fl/fl mice
(Jackson et al., 2005; Jackson et al., 2001) were maintained in viral-free condi-
tions on 129 SvJae background. Six- to twelve-week-old mice were used for
intranasal adenoviral-Cre infections (Jackson et al., 2001). Eight- to sixteen-
week-old Foxn1nu (nude) mice (Harlan, Jax, or Taconic) were used as recipi-
ents. All mouse experiments were approved by the CHB Animal Care and
Use Committee, accredited by AAALAC, and were performed in accordance
with relevant institutional and national guidelines and regulations. Tissue prep-
aration was as described (Jackson et al., 2001). Five H&E sections spaced 50
mm apart were analyzed for tumor formation by at least two investigators
including a pathologist with expertise in murine lung cancer. Immunostaining
of tissues was as described (Kim et al., 2005) with antisera raised against
mouse CC10 (Santa Cruz, sc-9773) and proSP-C (Chemicon, AB3786) with
donkey Alexa Fluor secondary antibodies (Molecular Probes). Triple-color
microscopy and imaging was performed with a Nikon 90i and a Roper Scien-
tific CCD camera and NIS-Elements software and processed with NIS-
Elements and Adobe Photoshop.FACS Analysis of Tumor Cells
Mice were euthanized with avertin overdose and lungs were dissected and
examined grossly for tumor formation. Tumors were dissected from the lungs
of Kras mice 6 to 10 months (average 7.5 months) or Kras;p53-flox mice 4 to
7 months (average 5.5 months) after adenoviral-Cre infection with as little
contribution from surrounding normal tissue as possible. We prepared tumor
tissue as described for normal lung (Kim et al., 2005) with Sca1-FITC,
CD45.2-Biotin, Pecam-Biotin, and Streptavidin-APC (PharMingen) with
7AAD (Molecular Probes) staining to eliminate dead cells. Cell sorting was per-
formed with a Cytomation MoFlo or a BD FACS Aria, and data were analyzed
with FloJo software (Tree Star).Tumor Transplants
Intratracheal transplants were as described (McLemore et al., 1987) with modi-
fications. Mice were anesthetized with avertin and supported on an intubation
stand. A halogen light was focused on the sternum, the trachea was visualized
by oral transillumination, and a 22G, 1-inch IV catheter (Fisher) was inserted
into the trachea. A 40–50 ml cell suspension in sterile PBS was pipetted into
the catheter and the mouse inhaled the cell suspension. Mice were monitored
for signs of lung tumor onset and euthanized for gross and histological analysis
upon signs of distress or at 6 months to 1 year after transplant.Statistical Analysis
TPC frequency was calculated with limiting dilution analysis with L-Calc Soft-
ware (StemCell Technologies). Fold enrichment for tumor-propagating activity
was determined by comparing the TPC frequency in populations of interest,
L-Calc provided p values. Except where indicated, Student’s t test was used
for comparing measurements between two conditions. GraphPad Prism
(GraphPad Software) and Mstat (McArdle Laboratory for Cancer Research,
University of Wisconsin) were used for graphing and statistical analyses.
p values less than 0.05 were considered significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.stem.2010.05.021.132 Cell Stem Cell 7, 127–133, July 2, 2010 ª2010 Elsevier Inc.ACKNOWLEDGMENTS
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